<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00392574</url>
  </required_header>
  <id_info>
    <org_study_id>OPT-099-001</org_study_id>
    <nct_id>NCT00392574</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Prulifloxacin Versus Placebo in Traveler's Diarrhea</brief_title>
  <official_title>A Multicenter, Double-Blind, Randomized Study to Compare The Safety and Efficacy of Prulifloxacin Versus Placebo in the Treatment of Acute Gastroenteritis in Adult Travelers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this pivotal Phase III study is to investigate the safety and efficacy of&#xD;
      prulifloxacin versus placebo in the treatment of subjects with acute bacterial&#xD;
      gastroenteritis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This double-blind trial will compare the safety and efficacy of prulifloxacin versus placebo&#xD;
      in adult travelers with acute gastroenteritis characterized by diarrhea with one or more of&#xD;
      the following signs or symptoms: nausea, vomiting, abdominal pain or cramping, fecal urgency,&#xD;
      moderate to severe gas-related symptoms, or tenesmus of â‰¤72 hours duration.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2006</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to last unformed stool</measure>
    <time_frame>Study days 1-3</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical cure based on relief of signs and symptoms</measure>
    <time_frame>Study days 1-3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiologic eradication rates</measure>
    <time_frame>Study days 1-3</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">282</enrollment>
  <condition>Acute Gastroenteritis in Adult Travelers</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prulifloxacin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prulifloxacin</intervention_name>
    <description>Tablet</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tablet</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of Acute Bacterial Gastroenteritis;&#xD;
&#xD;
          -  Traveler from Industrialized Country;&#xD;
&#xD;
          -  Capable of giving Informed Consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Fever (&gt;100.3 degrees);&#xD;
&#xD;
          -  Pregnant or Breast Feeding or Not using adequate birth control;&#xD;
&#xD;
          -  Known or Suspected (co-)Infection with non-bacterial pathogen;&#xD;
&#xD;
          -  Symptoms of Gastroenteritis of &gt;72 hours;&#xD;
&#xD;
          -  Bloody Diarrhea;&#xD;
&#xD;
          -  Concomitant antibacterial with activity against enteric bacterial pathogens;&#xD;
&#xD;
          -  History of IBD;&#xD;
&#xD;
          -  Unable/Unwilling to comply with study protocol;&#xD;
&#xD;
          -  &gt; 2 doses of anti-diarrheal medication within 24 hours;&#xD;
&#xD;
          -  Antimicrobial Treatment within 30 days&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Herbert Dupont, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Texas</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>INC Research</name>
      <address>
        <city>New Hope</city>
        <state>Pennsylvania</state>
        <zip>18938</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2010</verification_date>
  <study_first_submitted>October 24, 2006</study_first_submitted>
  <study_first_submitted_qc>October 25, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 26, 2006</study_first_posted>
  <disposition_first_submitted>August 27, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>August 27, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">August 31, 2010</disposition_first_posted>
  <last_update_submitted>April 27, 2015</last_update_submitted>
  <last_update_submitted_qc>April 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 15, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gastroenteritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroenteritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prulifloxacin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

